Geneva Capital Management LLC Lowers Holdings in Certara, Inc. (NASDAQ:CERT)

Geneva Capital Management LLC reduced its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 0.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 5,458,600 shares of the company's stock after selling 51,609 shares during the quarter. Geneva Capital Management LLC owned about 3.39% of Certara worth $58,134,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in Certara during the fourth quarter valued at $3,628,000. Proficio Capital Partners LLC bought a new stake in shares of Certara in the 4th quarter worth about $148,000. M&T Bank Corp raised its position in shares of Certara by 41.9% during the 4th quarter. M&T Bank Corp now owns 163,933 shares of the company's stock valued at $1,746,000 after buying an additional 48,381 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Certara by 8.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 757,392 shares of the company's stock valued at $8,066,000 after acquiring an additional 57,817 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in Certara by 169.0% in the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock worth $21,248,000 after acquiring an additional 1,253,385 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CERT has been the topic of a number of recent research reports. William Blair restated a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Barclays increased their price target on Certara from $12.00 to $13.00 and gave the company an "equal weight" rating in a report on Friday, February 28th. Stephens reaffirmed an "overweight" rating and set a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Finally, TD Cowen began coverage on shares of Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price on the stock. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $15.83.

Remove Ads

Certara Trading Down 3.9 %

CERT stock traded down $0.46 during midday trading on Monday, reaching $11.27. The company's stock had a trading volume of 1,888,940 shares, compared to its average volume of 984,759. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.39. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -56.35, a PEG ratio of 9.29 and a beta of 1.60. The stock has a fifty day simple moving average of $12.56 and a two-hundred day simple moving average of $11.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.